Equity intelligence report • July 05, 2026
Thermo Fisher Scientific Inc. has demonstrated remarkable financial performance, achieving a 19% revenue growth in Q2 2022, totaling $11.82 billion, driven by strong sales in its Analytical Instruments segment and strategic expansion initiatives. The company has successfully navigated challenges, including a decline in COVID-19 testing product sales. Highlighting investor confidence, 101 hedge funds have backed the stock, and the company raised its guidance for the upcoming quarter to $9.84 billion, reflecting a year-over-year increase. This growth continues to build on prior strategic acquisitions and improvements in core business segments.
Click a month on the chart to update the report below.
